FDA warns Novo Nordisk broke safety reporting rules

FDA warns Novo Nordisk broke safety reporting rules

Federal regulators have warned the maker of Ozempic and Wegovy that it failed to report possible drug side effects to the government.

Why did the FDA warn Novo Nordisk about GLP‑1 side effects?

What regulators found and why it matters The U.S. regulator sent a formal warning to the maker of widely used GLP‑1 medicines after concluding the company failed to report suspected adverse events in the way federal rules require. The flagged drugs, prescribed for diabetes and increasingly for…